medigraphic.com

2008, Number 4

<< Back

Rev Hosp Jua Mex 2008; 75 (4)

Micosis fungoides. Presentación de un caso clínico

García RS, Tejeda RM

Language: Spanish
References: 30
Page: 300-307
PDF size: 150.90 Kb.


ABSTRACT

Introduction. The mycosis fungoides is a cutaneos T-cell lymphoma, the most comun of this lymphomas. Clinical case. Male of 69 years old, seven months with erythematous patch in the thorax, plaques in the dorsal region, tumor in left shoulder and right groin. Histopathologic result. Diffuse Lymphoma No Hodgkin. The treatment is beginning with CHOP chemotherapy. Later, the patient with CNS infiltrate signs, without outcome to rescue chemotherapy, the patient died for involved in CNS. Discussion. The mycosis fungoides staging decree the treatment and prognosis. The treatment can be categorized into topical and systemic, however, the mycosis fungoides is not curable. Conclusion. The clinical staging is very important, because the predictive factors stablemen the more optimal treatment. In our center the more usual treatment is the chemotherapy, however the mycosis fungoides have high mortality.


REFERENCES

  1. Jahn S, Walden P. Cutaneous Malignat Lyphomas. Inmunol Today 1998; 19(3): 70-3.

  2. Rojas-Espinosa O. Inmunología. 2a Ed. México: Panamericana; 2004, p. 374.

  3. Girardi M, Heald PW, Wilson LD. Medical progress. The Pathogenesis of Mycosis Fungoides. N Engl J Med 2004; 350: 1978-88.

  4. Robert C, Kupper TS. Inflammatoryskin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-28.

  5. Lessin S, Vowells B, Rock A. Retroviruses and cutaneous T cell lymphoma. Dermatol Clin 1994; 12: 243-53.

  6. Morales Suarez-Varela MM, Llopis GA, Marquina VA, Bell J. Mycosis fungoides: review of epidemiological observations. Dermatology 2000; 201: 21-8.

  7. Juárez NL, Rincón PC. Linfomas Cutáneos: Fisiopatología y Clasificación. Rev Mex Dermatología 2005; 49(3): 109-22.

  8. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.

  9. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.

  10. Willemze R, Elaine S, Berti SE, et al. WHO-EORTC Classification for Cutaneous Lymphoma. Blood 2005; 105(19): 3768-85.

  11. Wood GS, Greenberg HL. Diagnosis, Staging and Monitoring of Cutaneous T-Cell Lymphoma. Dermatol Ther 2003; 16(4): 269-75.

  12. Drummer R, Schwarz T. Cytokines as regulatory protein in lymphoproliferative skin infiltrates. Dermatol Clin 1994; 12: 283-94.

  13. Franck N, Carlotti A, Gorin I, Buffet M, Mateus Ch, Dupin N, et al. Pathology of skin cutaneous lymphoma. 2000, p. 1369-95.

  14. Mycosis fungoides. Arch dermatol/vol 138, Feb, 2002.

  15. Cutaneous Lymphomas. Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma and Neutrophilic Dermatosis. Arch Dermatol 2005; 141: 353-6.

  16. Smith NP. Histologic criteria for early diagnosis of cutaneous T cell Lymphoma. Dermato Clin 1994; 12: 315-22.

  17. Warnke R, Kohler S, Hoppe RT, Kim YH. Staging Accuracy in Mycosis Fungoides and Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography. Arch Dermatol 2006; 142: 577-84.

  18. Sareeta RS, Parker BB. Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides. Dermatology Nursing 2006; 18(6).

  19. Colín GEI. Linfomas Cutáneos. Revisión de Casos. México: UNAM Facultad de Medicina; 2006.

  20. Smoller BR, Santucci M, Wood GS, et al. Histopathology and Genetics of Cutaneous T Cell Lymphoma. Hematol Oncol Clin North Am 2003; 17(6): 1277-311.

  21. Tsai EY, Taur A, Espinosa L, Andrew Q, Johnson D, Dick S, et al. Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids. Arch Dermatol 2005; 141: 1117-20.

  22. Kuzel TM. Systemic Chemotherapy for the Traetment of Mycosis Fungoides and Sezary Syndrome. Dermatol Ther 2003; 16(4): 355-61.

  23. Yanagi T, Shimizu T, Ujiie H, Ito M, Abe R, Tsuji-Abe Y, et al. Peginterferon Alfa-2b for Mycosis Fungoides. Arch Dermatol 2006; 142.

  24. Assaf C, Hummel M, Zemlin M, Steinhoff M, Geilen CC, Stein H, Orfanos CE. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis. J Clin Pathol 2004; 57: 1325-8.

  25. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-33.

  26. Quiros P, Kacinski BM, Wilson LD. Extent of skin involvement as a prognostic indicator of disease free and overall survival in patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996; 77: 1912-7.

  27. Weder P, Anliker M, Itin P, et al. Familial Cutaneous Mycosis Fungoides. Successuful Treatment with Alemtuzumab. Dermatology 2004; 208(3): 281-3.

  28. Smith BD, Wilson LD. Management of Mycosis Fungoides. Part 1. Diagnosis, Staging and Prognosis. Oncology 2003; 17(9); 1281-8.

  29. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150-9.

  30. Weinstock MA, Gardstein B. Twenty year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89: 1240-4.




2020     |     www.medigraphic.com